Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/neg monocytes mediates chemotherapy resistance

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Dogan, Ahmet ^b  

^a Jenny)   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemoresistance; Heat shock protein; Lymphoma; Monocyte; Myeloid derived suppressor cells

Indexed keywords

CASPASE 3; CD14 ANTIGEN; DOXORUBICIN; HEAT SHOCK PROTEIN 27; HLA DR ANTIGEN; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MONOCYTE; MYELOID PROGENITOR CELL; NORMAL HUMAN; PROTEIN EXPRESSION ASSAY;

EID: 84942861187     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.996470     Document Type: Article

References (33)

1. Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012; 17 Suppl 1:S93-7; PMID:22507791; http://dx. doi. org/10. 1179/102453312X13336169156014.
2. Zaja F, Federico M, Vitolo U, Zinzani PL. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Leuk Lymphoma 2014; 55:988-98; PMID:23865835; http://dx. doi. org/10. 3109/10428194. 2013. 825903
3. Rachinel N, Salles G. The host-tumor interface in Bcell non-Hodgkin lymphoma: a new world to investigate. Curr Hematol Malig Rep 2009; 4:196-201; PMID:20425408; http://dx. doi. org/10. 1007/s11899-009-0026-1
4. Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011; 29:1803-11; PMID:21483013; http://dx. doi. org/10. 1200/ JCO. 2010. 33. 3252
5. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR (low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117:872-81; PMID:21063024; http://dx. doi. org/10. 1182/blood-2010-05-283820
6. Talmadge JE, Gabrilovich DI. History of myeloidderived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx. doi. org/ 10. 1038/nrc3581
7. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 2013; 57:172-84; PMID:24203443; http://dx. doi. org/10. 1007/s12026-013-8455-2
8. Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA, Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010; 12:631-44; PMID:20179016; http://dx. doi. org/10. 1093/neuonc/ noq001
9. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010; 70:443-55; PMID:19902470; http://dx. doi. org/10. 1002/pros. 21078
10. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62:1421-30; PMID:23764929; http://dx. doi. org/ 10. 1007/s00262-013-1447-1
11. Rudolph BM, Loquai C, Gerwe A, Bacher N, Steinbrink K, Grabbe S, Tuettenberg A. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol 2014; 23:202-4; PMID:24495013; http://dx. doi. org/10. 1111/exd. 12336
12. Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS, Dietz AB. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012; 156:674-6; PMID:22050346; http://dx. doi. org/10. 1111/j. 1365-2141. 2011. 08902. x
13. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED et al. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 2013; 1:7; PMID:25512872; http://dx. doi. org/ 10. 1186/2051-1426-1-7
14. Khalifa KA, Badawy HM, Radwan WM, Shehata MA, Bassuoni MA. CD14 HLA-DR low/ monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int J Lab Hematol 2014; 36:350-55; PMID:24636145; http://dx. doi. org/10. 1111/ijlh. 12203
15. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22-35; PMID:19941314; http://dx. doi. org/ 10. 1002/eji. 200939903
16. Drakos E, Rassidakis GZ, Lai R, Herling M, O'Connor SL, Schmitt-Graeff A, McDonnell TJ, Medeiros LJ. Caspase-3 activation in systemic anaplastic large-cell lymphoma. Mod Pathol 2004; 17:109-16;PMID:14657946; http://dx. doi. org/10. 1038/modpathol. 3800039
17. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935-43; PMID:9242521; http://dx. doi. org/0006-4971/97/ 9003-0142
18. De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol 2000; 165:3951-8; PMID:11034403; http://dx. doi. org/10. 4049/ jimmunol. 165. 7. 3951
19. Kaiser F, Steptoe A, Thompson S, Henderson B. Monocyte cytokine synthesis in response to extracellular cell stress proteins suggests these proteins exhibit network behaviour. Cell Stress Chaperones 2014; 19:135-44; PMID:23775284; http://dx. doi. org/ 10. 1007/s12192-013-0440-0
20. Laudanski K, De A, Miller-Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. Eur J Immunol 2007; 37:2812-24; PMID:17823891; http://dx. doi. org/ 10. 1002/eji. 200636993
21. Banerjee S, Lin CF, Skinner KA, Schiffhauer LM, Peacock J, Hicks DG, Redmond EM, Morrow D, Huston A, Shayne M et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res 2011; 71:318-27; PMID:21224361; http://dx. doi. org/10. 1158/ 0008-5472. CAN-10-1778
22. Ciocca DR, Vargas-Roig LM. Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcell Biol 2002; 28:205-18; PMID:11908061; http://dx. doi. org/ 10. 1007/978-3-642-56348-5_11
23. Thanner F, Sutterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, Dietl J, Gassel AM, Müller T. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005; 25:1649-53; PMID:16033076
24. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 2014; 32:3059-68; PMID:25113753; http://dx. doi. org/10. 1200/JCO. 2013. 54. 8800
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; http://dx. doi. org/10. 1200/JCO. 2006. 09. 2403
26. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008; 103:270-83; PMID:17516511; http://dx. doi. org/10. 1002/jcb. 21405
27. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313-23; PMID:19038878; http:// dx. doi. org/10. 1056/NEJMoa0802885
28. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58:529-32; PMID:18705775; http://dx. doi. org/10. 1111/j. 1440-1827. 2008. 02268. x
29. Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y, Ishikawa J, Tominaga N, Sakoda H, Take H et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60:313-9; PMID:22211289; http://dx. doi. org/10. 1111/j. 1365-2559. 2011. 04096. x
30. Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 2007; 13:2855-64; PMID:17504983; http://dx. doi. org/10. 1158/1078-0432. CCR-06-2090
31. Aloy MT, Hadchity E, Bionda C, Diaz-Latoud C, Claude L, Rousson R, Arrigo AP, Rodriguez-Lafrasse C. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int J Radiat Oncol Biol Phys 2008; 70:543-53; PMID:17980509; http://dx. doi. org/ 10. 1016/j. ijrobp. 2007. 08. 061
32. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63:6174-7; PMID:14559800; http://dx. doi. org/10. 1182/blood-2003-08-2873
33. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, Ziesmer S, Dogan A, Witzig TE. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012; 119:2844-53; PMID:2323454; http://dx. doi. org/ 10. 1182/blood-2011-10-388538